Prescott Group Capital Management L.L.C. Purchases Shares of 90,000 WAVE Life Sciences Ltd. $WVE

Prescott Group Capital Management L.L.C. purchased a new stake in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 90,000 shares of the company’s stock, valued at approximately $1,530,000. Prescott Group Capital Management L.L.C. owned 0.05% of WAVE Life Sciences as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in WVE. CWM LLC grew its stake in shares of WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares during the period. Bessemer Group Inc. grew its stake in shares of WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after purchasing an additional 9,135 shares during the period. Russell Investments Group Ltd. grew its stake in shares of WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock valued at $73,000 after purchasing an additional 9,284 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of WAVE Life Sciences by 44.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock valued at $76,000 after purchasing an additional 3,609 shares during the period. Finally, Prudential Financial Inc. bought a new position in shares of WAVE Life Sciences during the 2nd quarter valued at approximately $80,000. 89.73% of the stock is currently owned by institutional investors.

WAVE Life Sciences Trading Up 0.8%

Shares of NASDAQ:WVE opened at $6.19 on Thursday. The stock has a 50 day moving average of $8.37 and a 200 day moving average of $11.19. WAVE Life Sciences Ltd. has a 12-month low of $5.02 and a 12-month high of $21.73. The company has a market cap of $1.19 billion, a PE ratio of -5.84 and a beta of -1.32.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.21. WAVE Life Sciences had a negative return on equity of 56.76% and a negative net margin of 255.70%.The company had revenue of $38.25 million for the quarter, compared to analysts’ expectations of $8.45 million. Equities research analysts predict that WAVE Life Sciences Ltd. will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Chris Francis sold 33,194 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total value of $499,569.70. Following the transaction, the insider directly owned 61,867 shares of the company’s stock, valued at approximately $931,098.35. The trade was a 34.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 24.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on WVE. Wedbush boosted their price objective on WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Canaccord Genuity Group cut their price objective on WAVE Life Sciences from $52.00 to $43.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Wall Street Zen upgraded WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Cantor Fitzgerald boosted their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Monday, April 20th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, WAVE Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.25.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.